The $400 Billion Orphan: How Rare Disease Drugs Became Pharma's Most Resilient Franchise

There is a number buried in a report released Thursday that deserves more attention than it will probably receive. According to Evaluate's 2026 Orphan Drug Report, global sales of rare disease medicines are projected to exceed $400 billion by 2032, representing more than 21 percent of all prescription pharmaceutical sales worldwide. To put that in context: the entire global prescription drug market was roughly $400 billion twenty years ago. The orphan drug sector, built on the premise of serving patients too few in number to attract commercial interest, has quietly become one of the most commercially dominant forces in modern medicine.

The report, published March 12, arrives at a moment of genuine tension for the rare disease field. The FDA has been, in Evaluate's own characterization, "temperamental" toward rare disease drug applications in recent months, rejecting programs from UniQure, Regenxbio, and Biohaven in ways that have rattled developers and prompted a congressional investigation. The GLP-1 obesity drug boom is pulling capital and scientific attention toward large-population indications. And pricing pressure from payers, amplified by the Inflation Reduction Act's negotiation framework, has introduced new uncertainty into the economics of rare disease development. Against that backdrop, a forecast of $409 billion in annual orphan drug sales by 2032 reads less like a victory lap and more like a stress test that the sector appears, so far, to be passing.

The Companies Winning the Rare Disease Race

Johnson and Johnson is positioned to wear the orphan drug crown by 2032, with nearly $31 billion in projected rare disease sales. Its multiple myeloma franchise anchors that position: Darzalex is forecast to be the top-selling orphan drug globally at $11.8 billion, a figure that reflects the commercial durability of a subcutaneous formulation that has effectively doubled the franchise's market exclusivity window. Carvykti, the CAR-T therapy developed with Legend Biotech, adds another $6.3 billion to J&J's orphan portfolio. The company's dominance in this space is not accidental. It reflects a decade of disciplined investment in hematology and oncology, combined with a willingness to pursue combination strategies and label expansions that have extended the commercial life of its core assets.

The more interesting story in the rankings is the rise of argenx. The Dutch biotech, which derives its entire projected 2032 revenue from orphan drugs, is forecast to displace Pfizer in the company rankings with $11.2 billion in orphan sales, driven almost entirely by Vyvgart, its FcRn inhibitor for autoimmune diseases. Argenx's trajectory illustrates something important about where the orphan drug market is heading: the most durable franchises are increasingly built on platform mechanisms that can be applied across multiple rare indications, rather than single-disease programs that exhaust their commercial potential after one approval. Alnylam's Amvuttra, projected at $7.5 billion in 2032 sales for transthyretin amyloidosis, follows a similar logic. RNA interference is a platform. The diseases it addresses are rare. The commercial opportunity, it turns out, is not.

Policy Tailwinds and the IRA Revision

The report's bullish outlook is partly a function of recent policy changes that have materially improved the economics of rare disease development. Under the original Inflation Reduction Act, only drugs with a single orphan indication were exempt from Medicare price negotiations. That exemption has now been expanded, through the current administration's One Big Beautiful Bill Act, to cover drugs with multiple orphan indications. The practical effect is significant: drugs like Darzalex and Vyvgart, which have accumulated approvals across several rare conditions, can now protect their pricing across all of those indications rather than facing negotiation pressure once they step outside their original orphan designation. The Congressional Budget Office has estimated this expanded exemption could cost Medicare nearly $9 billion over ten years, which gives some sense of the commercial value it preserves for manufacturers.

The reauthorization of the Rare Pediatric Disease Priority Review Voucher program in early 2026 adds another layer of incentive. These vouchers, which can be sold to other companies for hundreds of millions of dollars, have historically been a meaningful source of non-dilutive capital for small rare disease developers. Their return to the toolkit matters particularly for the long tail of companies working on conditions that affect only a few thousand patients worldwide.

The Headwinds Are Real

The Evaluate report is careful not to paper over the genuine challenges facing the sector. The FDA's recent rejections of rare disease programs, particularly those relying on external control designs rather than randomized trials, have introduced a new layer of regulatory risk into development planning. The UniQure situation, in which the agency reversed course on an agreed approval pathway for a Huntington's disease gene therapy, was particularly damaging to confidence. When a company designs a multi-year development program around a regulatory agreement and then finds that agreement no longer holds, the cost is not just financial. It is the erosion of the predictability that makes long-horizon rare disease investment possible in the first place.

There is also a structural shift underway in the R&D pipeline that the report flags with some care. The share of rare disease candidates in overall drug development is expected to fall from a projected peak of 30 percent in 2027 to 22 percent by 2032. The GLP-1 wave is part of the explanation, as large pharmaceutical companies facing a collective $300 billion patent cliff have strong incentives to invest in large-population indications where the commercial upside is more immediate. China's emergence as a biotech licensing powerhouse adds competitive pressure on pricing, as molecules licensed from Chinese developers bring additional supply into markets that have historically been protected by scarcity.

What the $400 Billion Number Actually Means

The orphan drug market's resilience is, at its core, a story about the structural advantages that rare disease programs carry: extended market exclusivity, premium pricing, lower trial costs due to smaller patient populations, and a regulatory framework that has historically been more accommodating than the standard approval pathway. Those advantages have not disappeared. But they are being tested in ways they have not been before, by a more demanding FDA, by payers increasingly unwilling to accept premium pricing without robust evidence of clinical benefit, and by a capital market that is rediscovering the appeal of large-indication blockbusters after years of rare disease enthusiasm.

The $400 billion forecast is not a guarantee. It is a projection built on assumptions about regulatory stability, pricing power, and pipeline productivity that are all, to varying degrees, in flux. What the number does capture is the extraordinary transformation of a market that was created by legislation in 1983 to address a genuine market failure, and that has since become one of the most commercially sophisticated and scientifically productive segments of the pharmaceutical industry. Whether it can sustain that position through the turbulence ahead is the question that will define the next decade of rare disease medicine.